Regenerex Pharma (Regenerex Pharma) EBIT per Share : $-0.01 (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Regenerex Pharma EBIT per Share?

Regenerex Pharma's EBIT per Share for the three months ended in Dec. 2023 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Regenerex Pharma's EBIT per Share or its related term are showing as below:

PEPT's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Regenerex Pharma's EBIT for the three months ended in Dec. 2023 was $-0.24 Mil.

Regenerex Pharma EBIT per Share Historical Data

The historical data trend for Regenerex Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma EBIT per Share Chart

Regenerex Pharma Annual Data

Trend

Nov09

Nov10

Nov11

Nov12

Nov13

Nov14

Mar17

Mar18

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

0.01

Regenerex Pharma Quarterly Data
	May14	Aug14	Nov14	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-0.01	-

Regenerex Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Regenerex Pharma's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.071	/	277.113
=	-0.00

Regenerex Pharma's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.244	/	277.919
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Regenerex Pharma (OTCPK:PEPT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Regenerex Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerex Pharma (Regenerex Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108

Website

https://regenerexpharmainc.com

Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines